• Login
    View Item 
    •   RD&E Research Repository Home
    • All RD&E publications by year
    • 2019 RD&E publications
    • View Item
    •   RD&E Research Repository Home
    • All RD&E publications by year
    • 2019 RD&E publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease

    Thumbnail
    URI
    https://rde.dspace-express.com/handle/11287/621393
    Author
    Ballard, Clive
    Date
    2019
    Journal
    Journal of Alzheimer's Disease
    Type
    Clinical Trial
    Publisher
    IOS Press
    DOI
    10.3233/JAD-180595
    Rights
    Copyright ©2020 IOS Press All rights reserved.
    Metadata
    Show full item record
    Abstract
    This open-label extension study evaluated the long-term safety and tolerability of idalopirdine 60 mg/day as adjunctive therapy in patients with mild-moderate Alzheimer's disease (AD). This extension study was a continuation of Studies 1 and 2 of the Phase III development program for idalopirdine and comprised a 28-week open-label treatment period ("OLEX") and a subsequent 24-week open-label treatment period with memantine ("MEMOLEX") in selected patients. The previous studies had shown no evidence of efficacy with idalopirdine as adjunctive treatment to donepezil but with good tolerability (of 1,791 patients randomized, 1,609 [90%] completed the double-blind studies). Of those, 1,463 patients (91%) entered the open-label extension study. During the 28-week OLEX period, the percentage of patients having treatment-emergent adverse events (TEAEs) ranged between 51% and 59% across the treatment groups originating from the lead-in studies. During the subsequent 24-week MEMOLEX period, 51% of the patients had TEAEs. Increases in liver enzymes (occurring in 1-3% of trial participants) were transient and no new safety signals were observed with longer term exposure. No consistent effects demonstrating benefits with idalopirdine were observed on efficacy parameters when patients transitioned to 60 mg in the extension study. Overall, idalopirdine was safe and well tolerated when added to donepezil, and when memantine was added to a prior combination of idalopirdine and donepezil. There were no new safety signals observed with up to 18 months of exposure at the described doses to idalopirdine.
    Citation
    Frölich L et al. Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease. J Alzheimers Dis. 2019;67(1):303-313. doi:10.3233/JAD-180595
    Publisher URL
    https://content.iospress.com/openurl?genre=article&id=doi:10.3233/JAD-180595
    Collections
    • 2019 RD&E publications
    • Honorary contracts publications

    Browse

    All of RD&E Research RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    DSpace software copyright © 2002-2022  DuraSpace
    Contact Us | Send Feedback
    DSpace Express is a service operated by 
    Atmire NV